Aktienanalyse zu Natural Alternatives International Inc (NAII)NAIINatural Alternatives International Inc

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer's preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Natural Alternatives International Inc is not a good buy right now due to ongoing financial losses and a low RSI of 45.49, indicating potential weakness. The stock has a forward P/E of 13.61, suggesting it may be undervalued, but the significant net loss of $13.54 million in Q4 2026 raises concerns about profitability. The stock is currently trading at $1.11, which is 1.3% of its 52-week range, indicating it is near its low. Investors should be cautious as the company has seen a year-to-date change of -69.08%, reflecting substantial declines in value.